Protocol Ledger

Academic / Cooperative Group · Consolidated Sponsor Hub

Cedars-Sinai Medical Center: Clinical Trials & FDA Approval Profile

Cedars-Sinai Medical Center (Los Angeles, CA) sponsors 38 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 22 active protocols (12 recruiting now), 8 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)21.1%
Median Closed Enrollment vs National (145 pts)13 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Cedars-Sinai Medical Center
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)38
Active Pipeline (Recruiting Now)22 (12)
Completed vs Stopped Early8 / 8 (21.1%)
Median Closed Actual Enrollment13 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Cedars-Sinai Medical Center
Hospital Research SiteLocationShared Protocols
Cedars-Sinai Medical CenterLos Angeles, CA33

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Cedars-Sinai across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Cedars-Sinai Medical Center Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI